Cipro-A (Ciprofloxacin) is one of the most active fluorinated quinolones. Ciprofloxacin is active against both Gram-positive and Gram-negative bacteria. It is particularly active against Gram-negative bacteria, including Salmonella, Shigella, Campylobacter, Neisseria and Pseudomonas. Ciprofloxacin has moderate activity against Gram-positive bacteria such as Streptococcus pneumoniae and Strep. faecalis. It is active against Chlamydia and some
Mycobacteria. Most anaerobic organisms are not susceptible. The principal mode of action is the inhibition of DNA gyrase, which mediates the formation of supercoils of DNA.
Cipro-A 250 mg Tablet : Each film-coated tablet contains Ciprofloxacin (as hydrochloride) USP 250 mg.
Cipro-A 500 mg Tablet: Each film-coated tablet contains Ciprofloxacin (as hydrochloride) USP 500 mg.
Cipro-A 750 mg Tablet: Each film-coated tablet contains Ciprofloxacin (as hydrochloride) USP 750 mg.
Cipro-A Pellets for Suspension : After reconstitution each 5 ml suspension contains Ciprofloxacin (as hydrochloride) USP 250 mg.
Respiratory tract infections
Skin and soft tissue infections
Urinary tract infections
Gonorrhea and other sexually transmitted diseases
Bacterial gastrointestinal infections
Bone and joint infections
Dosage and Administration
Generally ciprofloxacin should be continued for at least 2 days after the signs and symptoms have disappeared, except for inhalational anthrax (Post -exposure). Patients whose therapy is started with Ciprofloxacin I.V. may be switched to
Ciprofloxacin Tablets or Suspension when clinically indicated at the discretion of the physician. Pediatric patients & adolescents (1- 17 years of age): Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli.
OR AS DIRECTED BY THE PHYSICIAN.
Ciprofloxacin should not be given in patients with known hypersensitivity to Ciprofloxacin or other quinolone antibiotics.
Ciprofloxacin may cause nausea, vomiting, abdominal pain, diarrhea, headache, dizziness, sleep disorders, rash, pruritus, anaphylaxis, photosensitivity, increase in blood urea, and creatinine, transient disturbances in liver enzymes and bilirubin, arthralgia and myalgia, blood disorders.
Ciprofloxacin should be used with caution in patients with epilepsy or a history of epilepsy, in hepatic or renal impairment, in pregnancy, during breast-feeding and in children or adolescents. Avoid excessive alkalinity of urine and ensure adequate fluid intake.
Use in Pregnancy and Lactation
The safety and effectiveness of Ciprofloxacin in pregnant and lactating women have not been established.
Antacids and other cations: Early investigational trials with quinolones revealed decreased Ciprofloxacin absorption when co-administered with magnesiumaluminium antacids.
Theophylline: Theophylline serum concentrations have been found to be markedly elevated when co-administered with Ciprofloxacin.
Others: Rifampicin may induce the metabolism of Ciprofloxacin, leading to lower serum concentrations and failure of therapy. The combination of Ciprofloxacin and chloramphenicol may be antagonistic.
Direction for Reconstitution of suspension
Shake the bottle to loosen the pellets. Pour 50 ml (measure with the provided 10 ml measuring cup) boiled & cooled water into the bottle and shake well until all the pellets is dispersed. The reconstituted suspension should be used within 14 days of preparation if kept in room temperature or in a refrigerator. Shake the bottle well before each use.
Cipro-A 250 mg Tablet : Each box containing 310 tablets in blister strips.
Cipro-A 500 mg Tablet : Each box containing 54 tablets in Alu-Alu blister strips.
Cipro-A 750 mg Tablet : Each box containing 45 tablets in blister strips.
Cipro-A Pellets for Suspension: Each carton contains required amount of
pellets to prepare 60 ml suspension in glass bottle and a 10 ml measuring cup.